Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
| العنوان: | Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis |
|---|---|
| المؤلفون: | Pascale Exer, Giorgio Tamborrini, Pascal Zufferey, Burkhard Möller, Adrian Ciurea, Monika Hebeisen, Michael John Nissen, Raphael Micheroli, Almut Scherer |
| المساهمون: | University of Zurich, Ciurea, Adrian |
| المصدر: | PLoS ONE PloS one, vol. 14, no. 5, pp. e0216746 PLoS ONE, Vol 14, Iss 5, p e0216746 (2019) Hebeisen, Monika; Scherer, Almut; Micheroli, Raphael; Nissen, Michael J; Tamborrini, Giorgio; Möller, Burkhard; Zufferey, Pascal; Exer, Pascale; Ciurea, Adrian (2019). Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. PLoS ONE, 14(5), e0216746. Public Library of Science 10.1371/journal.pone.0216746 <http://dx.doi.org/10.1371/journal.pone.0216746> PLOS ONE, Vol. 14, No 5 (2019) P. e0216746 |
| بيانات النشر: | Public Library of Science, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, Time Factors, Physiology, medicine.medical_treatment, Ankylosing Spondylitis, Cancer Treatment, Biochemistry, Etanercept, White Blood Cells, Animal Cells, Immune Physiology, Medicine and Health Sciences, 610 Medicine & health, ddc:616, Innate Immune System, Multidisciplinary, Pharmaceutics, Hazard ratio, Anti-Inflammatory Agents, Non-Steroidal, 10051 Rheumatology Clinic and Institute of Physical Medicine, Antibodies, Monoclonal, Middle Aged, C-Reactive Proteins, TNF inhibitor, Oncology, Antirheumatic Agents, Medicine, Cytokines, Female, Cellular Types, medicine.drug, Research Article, Adult, musculoskeletal diseases, medicine.medical_specialty, Drug Synthesis, Science, Immune Cells, Immunology, 1100 General Agricultural and Biological Sciences, Gastroenterology and Hepatology, Autoimmune Diseases, Drug Therapy, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, Adalimumab/administration & dosage, Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Antibodies, Monoclonal/administration & dosage, Antirheumatic Agents/administration & dosage, Etanercept/administration & dosage, Humans, Infliximab/administration & dosage, Spondylarthritis/drug therapy, Tumor Necrosis Factor Inhibitors/administration & dosage, Spondylarthritis, Adalimumab, medicine, Ankylosing spondylitis, 1000 Multidisciplinary, Blood Cells, Proportional hazards model, business.industry, Pharmaceutical Processing Technology, Inflammatory Bowel Disease, Biology and Life Sciences, Proteins, Cell Biology, Molecular Development, medicine.disease, Golimumab, Infliximab, Immune System, 570 Life sciences, biology, Clinical Immunology, Tumor Necrosis Factor Inhibitors, Clinical Medicine, business, Developmental Biology |
| الوصف: | ObjectivesTo compare drug survival in patients with axial spondyloarthritis treated with different TNF inhibitors in standard dosage.MethodsPatients fulfilling the Assessment in SpondyloArthritis international Society classification criteria for axial spondyloarthritis in the Swiss Clinical Quality Management cohort were included in this study if a first TNF inhibitor on standard dosage was started after recruitment and if a baseline visit was available. Drug maintenance up to drug discontinuation or dose escalation was compared between TNF inhibitors with multiple adjusted Cox proportional hazards models and multiple imputation for missing baseline covariate data.ResultsA total of 966 patients were included (adalimumab 344, etanercept 237, golimumab 214, infliximab 171). Patients on certolizumab (n = 18) were excluded. Patients starting golimumab had lower disease activity as well as better physical function and quality of life in comparison to patients starting another drug. A higher proportion of patients starting infliximab had a history of extra-articular manifestations. Drug dosage was more often escalated during follow-up in patients treated with infliximab than with subcutaneously administered agents. However, no significant differences in time up to drug discontinuation or dose escalation were observed in multiple adjusted analyses if treatment was initiated after 2009, when all 4 TNF inhibitors were available: hazard ratio for infliximab versus etanercept 1.16 (95% confidence interval 0.80; 1.67), p = 0.44, for golimumab versus etanercept 0.80 (0.58; 1.10), p = 0.17 and for adalimumab versus etanercept 0.93 (0.69; 1.26), p = 0.66.ConclusionIn axial spondyloarthritis, drug survival with standard doses of different TNF inhibitors is comparable. |
| وصف الملف: | pone.0216746.pdf - application/pdf; application/pdf |
| اللغة: | English |
| تدمد: | 1932-6203 |
| DOI: | 10.7892/boris.135058 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208a397e0780c903991f23ed688df78f |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....208a397e0780c903991f23ed688df78f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|---|
| DOI: | 10.7892/boris.135058 |